Statistically conclusive or suggested result Inconclusive results Uncertain results Safety results

mEC - 2nd line (L2) metastatic/advanced - esophageal cancer (mEC) mEC - 2nd line (L2)

versus Standard of Care (SoC)
pembrolizumab alone vs. Standard of Care (SoC) 1 noneinconclusive results for: deaths (OS); AE (any grade)--